Aberrant expressions of AP-2α splice variants in pancreatic cancer

Catherine Carrière, Sarah Mirocha, Sophie Deharvengt, Jason R. Gunn, Murray Korc

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The present study was conducted to evaluate the expression and function of AP-2α isoforms in pancreatic ductal adenocarcinoma. Methods: The expression of AP-2α was evaluated at the RNA level by reverse transcription-polymerase chain reaction and at the protein level by Western blotting and immunofluorescence. Its function as a transcription factor was evaluated in transient transfection experiments: DNA binding properties by electromobility shift assay and transactivation capabilities by luciferase assay. Results: Multiple alternative splicing events of AP-2α messenger occurred in all human pancreatic cancer cell lines, including a novel isoform, termed variant 6, which was not present in HeLa cells. At the protein level, except for 1 cell line, all pancreatic cancer cell lines expressed high nuclear levels of AP-2α. We also showed that AP-2α expressed by the pancreatic cancer cell lines could bind its cognate recognition site and activate transcription. However, variant 6, although not able to activate transcription, did not act in a dominant negative manner when cotransfected with the full-length protein. Conclusions: Multiple isoforms of AP-2α are highly expressed in pancreatic cancer cell lines including a new isoform, AP-2α variant 6, which seems to be pancreatic cancer specific and is deprived of transcriptional activity.

Original languageEnglish (US)
Pages (from-to)695-700
Number of pages6
JournalPancreas
Volume40
Issue number5
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Protein Isoforms
Cell Line
Proteins
Alternative Splicing
Luciferases
HeLa Cells
Transcriptional Activation
Reverse Transcription
Fluorescent Antibody Technique
Transfection
Adenocarcinoma
Transcription Factors
Western Blotting
RNA
Polymerase Chain Reaction
DNA

Keywords

  • AP-2α isoforms
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Carrière, C., Mirocha, S., Deharvengt, S., Gunn, J. R., & Korc, M. (2011). Aberrant expressions of AP-2α splice variants in pancreatic cancer. Pancreas, 40(5), 695-700. https://doi.org/10.1097/MPA.0b013e31821f2715

Aberrant expressions of AP-2α splice variants in pancreatic cancer. / Carrière, Catherine; Mirocha, Sarah; Deharvengt, Sophie; Gunn, Jason R.; Korc, Murray.

In: Pancreas, Vol. 40, No. 5, 07.2011, p. 695-700.

Research output: Contribution to journalArticle

Carrière, C, Mirocha, S, Deharvengt, S, Gunn, JR & Korc, M 2011, 'Aberrant expressions of AP-2α splice variants in pancreatic cancer', Pancreas, vol. 40, no. 5, pp. 695-700. https://doi.org/10.1097/MPA.0b013e31821f2715
Carrière C, Mirocha S, Deharvengt S, Gunn JR, Korc M. Aberrant expressions of AP-2α splice variants in pancreatic cancer. Pancreas. 2011 Jul;40(5):695-700. https://doi.org/10.1097/MPA.0b013e31821f2715
Carrière, Catherine ; Mirocha, Sarah ; Deharvengt, Sophie ; Gunn, Jason R. ; Korc, Murray. / Aberrant expressions of AP-2α splice variants in pancreatic cancer. In: Pancreas. 2011 ; Vol. 40, No. 5. pp. 695-700.
@article{fb69627b9ef740ba92e9066340495cf0,
title = "Aberrant expressions of AP-2α splice variants in pancreatic cancer",
abstract = "Objectives: The present study was conducted to evaluate the expression and function of AP-2α isoforms in pancreatic ductal adenocarcinoma. Methods: The expression of AP-2α was evaluated at the RNA level by reverse transcription-polymerase chain reaction and at the protein level by Western blotting and immunofluorescence. Its function as a transcription factor was evaluated in transient transfection experiments: DNA binding properties by electromobility shift assay and transactivation capabilities by luciferase assay. Results: Multiple alternative splicing events of AP-2α messenger occurred in all human pancreatic cancer cell lines, including a novel isoform, termed variant 6, which was not present in HeLa cells. At the protein level, except for 1 cell line, all pancreatic cancer cell lines expressed high nuclear levels of AP-2α. We also showed that AP-2α expressed by the pancreatic cancer cell lines could bind its cognate recognition site and activate transcription. However, variant 6, although not able to activate transcription, did not act in a dominant negative manner when cotransfected with the full-length protein. Conclusions: Multiple isoforms of AP-2α are highly expressed in pancreatic cancer cell lines including a new isoform, AP-2α variant 6, which seems to be pancreatic cancer specific and is deprived of transcriptional activity.",
keywords = "AP-2α isoforms, Pancreatic ductal adenocarcinoma",
author = "Catherine Carri{\`e}re and Sarah Mirocha and Sophie Deharvengt and Gunn, {Jason R.} and Murray Korc",
year = "2011",
month = "7",
doi = "10.1097/MPA.0b013e31821f2715",
language = "English (US)",
volume = "40",
pages = "695--700",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Aberrant expressions of AP-2α splice variants in pancreatic cancer

AU - Carrière, Catherine

AU - Mirocha, Sarah

AU - Deharvengt, Sophie

AU - Gunn, Jason R.

AU - Korc, Murray

PY - 2011/7

Y1 - 2011/7

N2 - Objectives: The present study was conducted to evaluate the expression and function of AP-2α isoforms in pancreatic ductal adenocarcinoma. Methods: The expression of AP-2α was evaluated at the RNA level by reverse transcription-polymerase chain reaction and at the protein level by Western blotting and immunofluorescence. Its function as a transcription factor was evaluated in transient transfection experiments: DNA binding properties by electromobility shift assay and transactivation capabilities by luciferase assay. Results: Multiple alternative splicing events of AP-2α messenger occurred in all human pancreatic cancer cell lines, including a novel isoform, termed variant 6, which was not present in HeLa cells. At the protein level, except for 1 cell line, all pancreatic cancer cell lines expressed high nuclear levels of AP-2α. We also showed that AP-2α expressed by the pancreatic cancer cell lines could bind its cognate recognition site and activate transcription. However, variant 6, although not able to activate transcription, did not act in a dominant negative manner when cotransfected with the full-length protein. Conclusions: Multiple isoforms of AP-2α are highly expressed in pancreatic cancer cell lines including a new isoform, AP-2α variant 6, which seems to be pancreatic cancer specific and is deprived of transcriptional activity.

AB - Objectives: The present study was conducted to evaluate the expression and function of AP-2α isoforms in pancreatic ductal adenocarcinoma. Methods: The expression of AP-2α was evaluated at the RNA level by reverse transcription-polymerase chain reaction and at the protein level by Western blotting and immunofluorescence. Its function as a transcription factor was evaluated in transient transfection experiments: DNA binding properties by electromobility shift assay and transactivation capabilities by luciferase assay. Results: Multiple alternative splicing events of AP-2α messenger occurred in all human pancreatic cancer cell lines, including a novel isoform, termed variant 6, which was not present in HeLa cells. At the protein level, except for 1 cell line, all pancreatic cancer cell lines expressed high nuclear levels of AP-2α. We also showed that AP-2α expressed by the pancreatic cancer cell lines could bind its cognate recognition site and activate transcription. However, variant 6, although not able to activate transcription, did not act in a dominant negative manner when cotransfected with the full-length protein. Conclusions: Multiple isoforms of AP-2α are highly expressed in pancreatic cancer cell lines including a new isoform, AP-2α variant 6, which seems to be pancreatic cancer specific and is deprived of transcriptional activity.

KW - AP-2α isoforms

KW - Pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=79959818777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959818777&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e31821f2715

DO - 10.1097/MPA.0b013e31821f2715

M3 - Article

VL - 40

SP - 695

EP - 700

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -